The Peptide Research Podcast cover art

The Peptide Research Podcast

The Peptide Research Podcast

By: NRG BioLabs LLC
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary

Educational-based podcast providing the latest in scientific peptide research. We take a complex topic and make it easy for everyone to understand.


https://peptideresearch.us

© 2026 The Peptide Research Podcast
Alternative & Complementary Medicine Hygiene & Healthy Living
Episodes
  • BPC-157, TB-500, and the Wolverine Stack: Single Peptides vs. Combined Compounds Explained
    Nov 20 2026

    Why do researchers frequently group BPC-157 and TB-500 together under the nickname "the Wolverine stack"—and how do scientists decide between studying one peptide, using both separately, or working with a combined compound? In this episode of the PeptideResearch.us Podcast, host Amy Andrews and research educator Todd Collins break down the fascinating cellular science behind two of the most talked-about recovery peptides in modern research.

    You'll learn how BPC-157 supports angiogenesis to clear metabolic traffic jams, how TB-500 upregulates actin to mobilize repair cells across damaged tissue, and why combining both mechanisms creates a powerful dual-pathway synergy. Whether you're curious about vascular signaling, cytoskeletal remodeling, or how multi-compound formulations work in laboratory models, this plain-English deep dive makes complex peptide science clear and approachable.

    Explore third-party Certificates of Analysis (COAs), lab testing standards, and educational resources at PeptideResearch.us

    BECOME AN NRG BIOLABS AFFILIATE
    Already the person your friends text with peptide questions?


    The NRG BioLabs affiliate program gives you your own custom Wholesale Peptides link. Share it with the people already asking. When they order through your link, you earn — and you keep earning every time they reorder. Recurring, not one and done.

    No inventory. No minimums. Just your link.

    Sign up: https://wholesalepeptides.us/affiliate-registration-2/

    Join our exclusive text and email club to receive VIP access to special promotions, limited-time discounts, product launches, and subscriber-only offers.

    Join here, its FREE! https://wholesalepeptides.us/insider-club/

    Show More Show Less
    10 mins
  • Overcoming Tirzepatide and Retatrutide Weight Loss Plateaus
    Nov 13 2026

    Click here to join our Discord: Real Peptide Talk

    Shop Research Compounds: https://wholesalepeptides.us

    Visit our blog: https://peptideresearch.us

    Join our Newsletter list: https://peptideresearch.us/newsletter

    Affiliate Program: https://wholesalepeptides.us/affiliate-registration-2/


    In this episode of the PeptideResearch.us Podcast, hosts Amy Andrews and Todd Collins (AI personas of Peptide Research) examine the inferential gap between group-level trial statistics and individual outcomes, the reason a reported mean can be accurate while describing no participant in the cohort. The discussion explores why aggregate summaries from Tirzepatide and Retatrutide research models cannot function as individual forecasts.


    The episode details measures of dispersion and the information loss inherent in reporting central tendency alone, highlighting the ecological fallacy as the formal name for transferring a group-level statistic to a single member. The conversation breaks down within-subject versus between-subject variance as distinct quantities answering distinct questions, the sensitivity of an arithmetic mean to a single extreme observation, responder and non-responder stratification as an alternative to averaging, bimodal distributions in which the mean occupies an unpopulated interval, and why mechanistic plausibility addresses expected central tendency while remaining silent on variance and individual position. Receptor-activity profiles are noted — Tirzepatide at GIP and GLP-1, Retatrutide at GIP, GLP-1 and glucagon — as an illustration of a mechanism argument that cannot substitute for outcome data.


    Listeners will gain an understanding of why dispersion carries more information than a mean, why stratified reporting is more transparent than aggregation, why a plausible mechanism is not evidence, and how rigorous analytical standards like third-party testing and Certificates of Analysis ensure research integrity.


    BECOME AN NRG BIOLABS AFFILIATE
    Already the person your friends text with peptide questions?


    The NRG BioLabs affiliate program gives you your own custom Wholesale Peptides link. Share it with the people already asking. When they order through your link, you earn — and you keep earning every time they reorder. Recurring, not one and done.

    No inventory. No minimums. Just your link.

    Sign up: https://wholesalepeptides.us/affiliate-registration-2/

    Join our exclusive text and email club to receive VIP access to special promotions, limited-time discounts, product launches, and subscriber-only offers.

    Join here, its FREE! https://wholesalepeptides.us/insider-club/

    Show More Show Less
    8 mins
  • Retatrutide vs Semaglutide: October 2026 Trial Results
    Nov 10 2026

    Click here to join our Discord: Real Peptide Talk

    Shop Research Compounds: https://wholesalepeptides.us

    Visit our blog: https://peptideresearch.us

    Join our Newsletter list: https://peptideresearch.us/newsletter

    Affiliate Program: https://wholesalepeptides.us/affiliate-registration-2/


    In this episode of the PeptideResearch.us Podcast, hosts Amy Andrews and Todd Collins (AI personas of Peptide Research) examine comparative trial design, the methodological difference between a direct randomized head-to-head and an indirect comparison assembled from separately conducted studies. The discussion explores why a reported head-to-head between Retatrutide and Semaglutide changes what can be inferred, and what such a design still cannot establish.


    The episode details confounding and the non-exchangeability of separate study populations, highlighting randomization and concurrent control as the mechanisms that make an observed difference attributable. The conversation breaks down the role of the active comparator in bounding any conclusion, placebo-controlled null-arm testing as an empirical estimate of measurement noise, allocation concealment and blinded assessment, and the distinction between sponsor-reported topline results and the peer-reviewed scientific record. Comparator selection is examined as a determinant of the research question itself, with Tirzepatide noted as absent from the reported comparison and therefore outside its inferential reach.


    Listeners will gain an understanding of why two independently measured results cannot be subtracted, why randomization and concurrency are what convert a difference into evidence, why every comparative claim is bounded by the arm it was measured against, and how rigorous analytical standards like third-party testing and Certificates of Analysis ensure research integrity.


    BECOME AN NRG BIOLABS AFFILIATE
    Already the person your friends text with peptide questions?


    The NRG BioLabs affiliate program gives you your own custom Wholesale Peptides link. Share it with the people already asking. When they order through your link, you earn — and you keep earning every time they reorder. Recurring, not one and done.

    No inventory. No minimums. Just your link.

    Sign up: https://wholesalepeptides.us/affiliate-registration-2/

    Join our exclusive text and email club to receive VIP access to special promotions, limited-time discounts, product launches, and subscriber-only offers.

    Join here, its FREE! https://wholesalepeptides.us/insider-club/

    Show More Show Less
    9 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.